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Abstract
Neurodegenerative disorders, such as Huntington’s disease (HD), Alzheimer’s 
disease (AD), and Parkinson’s disease (PD), are characterized by changes in the 
levels and activities of neurotrophic factors (NTFs), such as brain-derived neu-
rotrophic factor (BDNF). Gain-of-function and loss-of-function experiments 
demonstrate in fact the linkage between wild-type huntingtin (HTT) and gene 
transcription and intracellular transport of BDNF. In the present chapter, we will 
analyze the involvement of BDNF in HD and other neurodegenerative diseases. 
We will discuss the current BDNF technologies focusing on stem cell therapies that 
induce BDNF upregulation, for instance, the method of autologous mesenchymal 
stem cell (MSC) culturing in the presence of cocktail of BDNF inducers and factors 
(MSC/BDNF), genetic engineering of MSC and their use as a vector for BDNF gene 
delivery, and combined method of establishment of embryonic stem cell (ESC)-
derived BDNF-overexpressing neural progenitors, which is still at the preclini-
cal stage. Clinical trial that uses MSC/BDNF is already in course, while genetic 
engineering of MSC/BDNF is in perspective to treat adult and juvenile HD. The 
potential application of these technologies is beyond HD. Other neurodegenerative 
disorders such as Alzheimer’s and Parkinson’s diseases also can be further included 
in the list of clinical trials that use MSC/BDNF or even ESC/BDNF-overexpressing 
neural progenitors.
Keywords: brain-derived neurotrophic factor, stem cell technologies, Huntington’s 
disease
1. Introduction
It is common knowledge that learning and memory depend on controlled 
signaling processes at synapses and include the precise synaptic communication 
between neurons and other cellular associates. Thus, the brain-derived neuro-
trophic factor (BDNF) and its partners appeared as key regulators of synaptic 
plasticity, which is the ability of synapses to increase or decrease their activity [1–3]. 
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Generally, neuromodulators regulate neuronal plasticity; however, BDNF act as a 
mediator between synaptic plasticity and synaptic communication. In addition, 
BDNF can act in association with neurotransmitter signaling cascades showing 
immediate and helpful functions on synaptic plasticity [3]. Due to these properties, 
BDNF recently attracts much attention and became a leading strategy to stimulate 
neuronal and synaptic plasticity for potential protective and functionally restor-
ative treatments for neurological and psychiatric disorders [4, 5].
Actions of BDNF in normal brain function and links between BDNF and 
neurodegenerative diseases suggest therapeutic potential of BDNF in diseases such 
as Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s diseases (PD), 
amyotrophic lateral sclerosis (ALS), metabolic disorders (such as obesity), spinal 
cord injury, stroke, ischemia, etc. [6–8].
However, delivery of BDNF to the brain is challenging. The blood–brain barrier 
(BBB) obstructs drug delivery to the brain for the treatment of a wide range of 
central nervous system (CNS) diseases [9]. BDNF, a 27-kDa protein, has minimal 
BBB penetrability. BDNF also has a short half-life in the blood (0.92 min) and a 
poor pharmacokinetic profile. Systemic intravenous deliveries of BDNF are inef-
ficient, due to the BBB, and cause strong side effects. Direct injections of BDNF into 
the central nervous system are invasive and limited by diffusion restrictions. Thus, 
alternative strategies, such as BDNF-secreting stem cells, for delivery of neuropro-
tective drugs are critical for promoting their clinical potentials.
2. Brain-derived neurotrophic factor
BDNF is a member of the neurotrophin family and widely expressed in the 
mammalian brain [1]. Precursor BDNF (proBDNF) includes an N-terminal prodo-
main and a C-terminal mature domain. ProBDNF is synthesized in the endoplas-
mic reticulum (ER) and secreted from dense-core vesicles. After packaging into 
dense-core vesicles, ProBDNF is trafficked through either the regulated secretory 
pathway or the constitutive secretory pathway [10, 11]. ProBDNF is processed to 
mature BDNF by several alternative cellular mechanisms. ProBDNF can be cleaved 
within the endoplasmic reticulum by furin or within the trans-Golgi network in 
regulated secretory vesicles by proconvertase enzymes. If proBDNF reaches the 
extracellular milieu, it can be processed by plasmin, or become endocytosed, and 
then cleaved to produce mature BDNF. Mature BDNF comprises dimers of the 
mature domain [12, 13].
BDNF can function in a highly localized manner or at a distance [14, 15]. The 
fact that BDNF is expressed within the peripheral ganglia and is not restricted to 
neuronal target fields raises the possibility that BDNF exerts paracrine or autocrine 
actions on neurons and non-neuronal cells [16]. BDNF binds to tyrosine receptor 
kinase B (TrkB) and low-affinity nerve growth factor receptor (LNGFR), also 
known as CD271 and p75 (NTR) [8, 17]. BDNF has been shown to modulate the 
activity of various neurotransmitter receptors, such as the alpha-7 nicotinic recep-
tor [18]. BDNF has also been shown to interact with reelin, which is a large secreted 
extracellular matrix glycoprotein, and it supports the processes of neuronal migra-
tion and place in the developing brain through controlling cell–cell interaction 
signaling chain [19].
BDNF plays an important role in neurogenesis; neuronal differentiation, 
polarization, and guidance; and the survival of stem cells and their progenitors. 
The survival and differentiation of several classes of neurons in vitro, including the 
neural crest neurons, placode-derived sensory neurons, dopaminergic neurons in 
the substantia nigra, basal forebrain cholinergic neurons, hippocampal neurons, 
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and retinal ganglia cells, are enhanced by BDNF. BDNF affects behavior by influ-
encing the branching of differentiated neurons and the formation and maturation 
of spines and synapses. In the mature nervous network, amplification and enhance-
ment of neuronal circuit structure, modulation of synaptic plasticity, and regula-
tion of cognitive brain function (such as learning and memory) also depend on 
BDNF expression [4, 6–8, 20, 21].
The effects of mature BDNF are closely regulated. Even a small change in BDNF 
concentration may disturb the development of neural circuits and the regulation of 
brain function. Expression of BDNF is reduced among patients with Alzheimer’s 
[22, 23] and Huntington’s disease [7, 24]. Age-associated changes in BDNF-
mediated pathways have also been shown to enhance inflammation and increase 
myocardial injury after myocardial infarction in the aging heart [24, 25].
The unique role of BDNF in cognitive and affective behaviors suggests their 
possible use to treat cognitive deficits (Figure 1).
3.  BDNF biodistribution and serum levels in neurological and 
psychiatric disorders
The neocortex in the brain has morphologically stratified subdivisions into six 
layers: I, molecular layer; II, external granular; III, external pyramidal; IV, internal 
granular; V, internal pyramidal; and VI, multiform. BDNF mRNA levels vary 
between layers but are higher in Layer VI [26] (Figure 2).
The various types of afferent nerve fibers branch out in the cortex in different 
ways. The afferent fibers arriving from the thalamus nuclei terminate primar-
ily in the middle layers, predominantly in the dendritic leaflets of the IV lamina. 
Figure 1. 
The scheme of signaling involved BDNF synaptic effects and its maturation. The synthesis of BDNF from 
proBDNF in the endoplasmic reticulum is shown. ProBDNF binds to Golgi to enhance the proper folding of the 
mature domain. ProBDNF is cleaved by proteases at synapses and converted to mature BDNF. Mature BDNF 
binds to TrkB and glutamate released to stimulate ProBDNF transcription.
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The fibers of the other thalamic nuclei, coming from the cortical areas, ascend ver-
tically and diffuse into different layers depending on their origin (the fibers of the 
thalamus intralaminal nuclei mostly terminate in Layer VI, whereas the fibers of the 
cortical areas terminate mainly in Layers II and III). Cortical efferent fibers, such as 
afferents, go to other cortical areas or to subcortical areas. Most subcortical effer-
ences descend through the internal capsule and may or may not reach the level of 
the spinal cord. The blades most involved in these efferences are blade V (corticoid 
fibers, fibers for the brain stem and spinal cord) and lamina VI (corticothalamic 
fibers). Blade III is the largest source of corticocortical fibers [27].
Brain-derived neurotrophic factor is widely distributed in the central nervous 
system and has survival-promoting actions on a variety of CNS neurons. BDNF 
mRNA levels are relatively low during infancy and adolescence, peak during young 
adulthood, and are maintained at a constant level throughout adulthood and aging 
(Figure 3).
BDNF mRNA levels vary between layers, with Layer VI consistently higher than 
other layers [20, 28, 29]. The BDNF can be measured in blood samples and patients’ 
Figure 2. 
Neocortex in the brain.
Figure 3. 
BDNF throughout life.
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cerebrospinal fluid. The analyses BDNF levels in CNS in neurological and psychiat-
ric disorders showed to be different from those of normal invidious. Several studies 
showed a correlation between the BDNF level in serum and the clinical data for 
symptomatic patients [28].
Thus, the mean BDNF serum concentration was significantly lower in patients 
with Huntington’s disease than in healthy controls (P < 0.001). In patients with 
Huntington’s disease, the scale used to measure clinical parameters is Unified 
Huntington’s Disease Rating Scale (UHDRS). The UHDRS is a clinical evaluation 
including domains to assess the motor, cognitive, and behavioral functions and 
functional capacity (Huntington Study Group, 1996).
In patients with Huntington’s disease, serum BDNF levels are lower as motor and 
cognitive disorders progress, as measured by the UHDRS (Figure 4) [30].
No significant difference in BDNF levels in serum according to the subjects’ 
gender nor significant factor modifications related to the subjects’ age or to the time 
of day when blood was drawn (P > 0.05) were found [30]. A serum BDNF defi-
ciency in HD patients is in line with the previous works highlighting trophic factor 
Figure 4. 
BDNF decreasing with motor and cognitive impairment.
Figure 5. 
Correlation between CAG repetitions and BDNF levels in patients with Huntington’s disease.
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dysfunction in animal models and autopsy material [31–33]. This means that BDNF 
levels and CAG repeats are indicators for clinical prognosis; the higher the number 
of CAG repeats is, the worse the prognosis, and the lower the BDNF levels are, the 
patient is worse clinically (Figure 5) [31–33].
Several lines of evidence indicate that BDNF is essential in sustaining the physi-
ological processes of the normal, intact adult brain. BDNF has a role in modulating 
dendritic branching and dendritic spine morphology as well as synaptic plastic-
ity and long-term potentiation (LTP), which is a persistent increase in synaptic 
strength following a high-frequency stimulation of a chemical synapse. In this 
manner, BDNF influences learning and memory [8, 34, 35]. BDNF also modulates 
hypothalamic metabolic function, further reflecting the diversity of its role in the 
adult brain [6].
3.1 Drugs increasing BDNF level
Some drugs may increase endogenous BDNF levels in the brain (Figure 6) 
like antidepressants, lithium, and ampakines (class of drugs that act as posi-
tive modulators of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA)).
These drugs are already used for symptoms that arise in diseases concomitant 
with neurodegenerative diseases, such as mood swings and depression. The mecha-
nisms of action for increasing BDNF levels are still complex and not fully under-
stood [6, 36].
3.2 Factors affecting BDNF level
Animal studies show that exercise and a calorie-restricted diet can positively 
affect BDNF levels in various brain regions such as the cortex and hippocampus [6]. 
If this pattern can be replicated in humans, this information reinforces the impor-
tance of exercise orientation and a healthy diet throughout life, especially in the 
young adult phase, when humans have higher levels of BDNF production in order to 
have good neurological performance.
Figure 6. 
Drugs and factors that increase endogenous BDNF levels.
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4. BNDF therapeutic effect in neurodegenerative diseases
Neurodegenerative diseases have a continuous process of neuronal destruction 
and loss that can be delayed or even reversed with therapies that can improve the 
functional state of neurons. In theory, the earlier the diagnosis of these diseases, the 
greater the chance of the disease reaching a plateau and not progressing, conse-
quently increasing the chance that the patient will preserve more functionality. 
Based on this therapeutic potential, growth factors have been evaluated in patients 
with various neurological disorders, including ALS, peripheral neuropathy, and 
Huntington’s, Parkinson’s, and Alzheimer’s diseases.
4.1 Huntington’s disease
Huntington’s disease is a hereditary degenerative neurological disease. The most 
affected neurons are those that make up the extrapyramidal region but specifically 
the striatum (caudate and putamen nuclei). The genetic pattern of transmission is 
autosomal dominant, caused by the expansion of CAG triplicate repeats in the gene 
encoding the protein huntingtin [37].
The clinical form that expresses this lesion is evidenced by involuntary move-
ments (chorea) in the face, trunk, and limbs, difficulty in articulating the voice, gait 
difficulties, and balance and cognitive decline [38–40].
In Huntington’s disease, BDNF transport from the cortex to the striatum is 
impaired. Infusion of the BDNF protein into the striatum of HTT-mutant mice 
increases striatal neurons and improves motor function [39]. The use of ampakines 
has also been observed to increase BDNF levels in mice with beneficial results for 
the memory of these animals including [40].
The use of BDNF in humans would not act on the genetic cause of this disease 
but could slow down the progression of the disease providing a better quality of 
life for patients and maintaining functionality in daily activities and can be used as 
adjunctive therapy to currently available treatments.
4.2 Other neurodegenerative diseases
For other neurodegenerative diseases, BDNF is expected to act by improving 
cellular function through mechanisms involving the phosphoinositide 3-kinase 
and AKT and protein kinase (MEK)/extracellular signal-regulated kinase (ERK) 
pathway.
4.2.1 Amyotrophic lateral sclerosis
ALS is a neurological disease characterized by a progressive motor neuron atro-
phy, which leads to a generalized weakness and respiratory failure over a relatively 
rapid period of approximately 2 years. There was an old concept that ALS was an 
exclusively motor disease, but a cognitive impairment is now being observed as part 
of a frontal dementia.
The use of BDNF in this disease in both experimental animal models and later 
in human clinical studies could delay neuronal loss, improving the brain and spinal 
cord microenvironment [6].
4.2.2 Alzheimer’s disease
Alzheimer’s disease is a more common form of dementia and has an onset of 
insidious cognitive loss, progressive worsening of language, impaired visual–spatial 
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orientation, and executive functions, and the patient has no other causes of demen-
tia in clinical research such as infectious diseases, metabolic diseases, vascular 
diseases, use of medicines, and use of toxic substances, among others.
BDNF levels become deficient in the entorhinal cortex and the hippocampus in 
Alzheimer’s disease [22, 41, 42]. A series of studies was conducted in several animal 
models of Alzheimer’s disease to assess the effect of therapeutic application of 
BDNF to the entorhinal cortex [6, 43].
4.2.3 Parkinson’s disease
Parkinson’s disease is a neurodegenerative disorder that impairs motor function 
and cognitive ability. The progressive degeneration of dopaminergic neurons is 
reflected in the motor dysfunction of the patients.
BDNF treatment can prevent the loss of dopaminergic neurons in the substantia 
nigra. This is true in rodent animal models and nonhuman primates [44].
Parkinson’s disease is a condition where BDNF therapy is promising and may 
return minimal functional and perhaps even cognitive ability to patients in the 
future.
5. Mesenchymal stem cell-based BDNF therapy
Mesenchymal stem cells are adult stem cells capable of self-renewal and differ-
entiation into multiple lineages including cartilage, adipose, and bone. MSCs have 
been isolated from a wide range of sources including bone marrow (BM), umbilical 
cord, adipose tissue, multiple dental tissues, etc. Taking advantage of their mul-
tipotent, regenerative, and immunosuppressive properties, as well as tropisms to 
inflamed, hypoxic, and cancerous sites, MSCs have been used in various therapeutic 
studies, and MSC-based therapies have been shown to be safe. However, when 
applied alone, the efficacy in some MSC-based therapies remains low. To improve 
therapeutic efficacy, MSCs have been genetically modified to acquire targeted 
delivery function, therapeutic drug incorporation, and cell surface modification. To 
enhance their native properties, MSCs can also be genetically modified to overex-
press therapeutic proteins.
MSCs are known to promote tissue repair by expressing a variety of bioactive 
molecules and secreting substances such as cytokines and growth factors. MSCs 
naturally secrete BDNF at low levels, varying from 0 to 200 pg/mL (Table 1) 
[45–50]. Cell therapy in regenerative medicine requires MSCs that secrete high 
BDNF level and are safe for use in humans.
5.1 NurOwn-MSC
BrainStorm Stem Therapeutics developed the patented NurOwn® technology 
that uses autologous MSCs which grow in proprietary conditions (using cocktails of 
inducers and factors), converting them into biological factories secreting a variety 
of neurotrophic factors (NTFs), including BDNF. Bahat-Stroomza et al. reported 
that human bone marrow-derived MSCs produced an approximately 200 pg/mL  
and 1400 pg/mL BDNF at baseline and after BDNF induction, respectively 
(Table 1) [46, 51]. The later was tested in humans; the bone marrow-derived 
MSCs did not show toxicity or side effects. Finally, Gervois et al. showed BDNF 
value around 2–2.5 ng/mL per 1x105 MSC [52]. Currently, this technology is used 
in Phase 2 open-label, multicenter study of repeated intrathecal administration 
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of autologous MSC-NTF cells in progressive multiple sclerosis. This study was 
designed to provide preliminary data on the safety and efficacy of these cells 
(Table 2).
5.2 MSC/BDNF and HD preclinical study
BDNF gene has been successfully introduced into MSCs using viral vectors, such 
as adenovirus and lentivirus (Table 3). Viral infections produced an 80- to 180-fold 
increase in BDNF production, although the absolute BDNF concentration varied 
significantly among the different studies (Table 1) [48, 53, 54] and toxicity and side 
effects remain unknown. More recently, preclinical double-blinded study trans-
planted human MSC/BDNF intrastriatal (within the corpus striatum) in two strains 
of immune-suppressed HD transgenic mice: YAC128 and R6/2. Following MSC/
BDNF transplantation, atrophy in YAC128 mice decreased. This treatment reduced 
mice’s anxiety that was measured in the open-field assay and increased the mean life 
span of the R6/2 mice. It is interesting that both MSC and MSC/BDNF transplanta-
tions induced a significant increase in neurogenesis-like activity in R6/2 mice [54]. 
These cells provide a platform delivery system for future studies involving correc-
tive gene-editing strategies. Researches plan to submit an investigational new drug 
application to the Food and Drug Administration in order to develop Phase 1 safety 
and tolerability trial of MSC/BDNF in patients with Huntington’s disease [55].













n/if n/if 200 pg 106 [46]
hBM-MSC 7–9 n/if 20–188 pg n/if [47]
heMSC 74–196
hAD-MSC 35
hBM-MSC n/if 48 72.2 pg — [48]
hUC-MSC n/if 24 50 pg — [49]
hWJ-MSC n/if 37 pg n/if [50]
hBM-MSC, human bone marrow MSC; heMSC, human endometrial MSC; hAD-MSC, human adipose tissue-
derived MSC; hUC-MSC, human umbilical cord blood MSC; hWJ-MSC, human Wharton jelly MSC; n/if,  
not informed.
Table 1. 




















BDNF secretions observed in BM-MSCs that naturally secrete BDNF in comparison with NurOwn BM-MSC.
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6. Embryonic stem cell-derived neural progenitors/BDNF
Embryonic stem cells are pluripotent stem cells that propagated indefinitely. 
These cells can differentiate into cells of all three germ layers (endoderm, meso-
derm, and ectoderm). ESC from teratoma and embryoid body (EB) that mimics 
early embryonic development. These cells differentiate efficiently into neural 
progenitor and functional neurons. Therefore, they can be used to differentiate into 
striatal medium spiny neurons (MSNs) that are lost in HD. MSNs depend on BDNF 
activity, and different studies try to use exogenous BDNF for striatal neuroprotec-
tion in rodent striatum HD models. Therefore, ESC and induced pluripotent stem 
cells (iPSC) seem to be an appropriate cell source for HD and other neurodegenera-
tive diseases. Accordingly, ESC-derived neural progenitors overexpressing BDNF 
were transplanted into quinolinic acid (QA) chemical and two genetic HD mouse 
models (R6/2 and N171-82Q ). Thus, this study combined cell replacement and 
BDNF supply as a potential HD therapy approach. QA-lesioned mice demonstrate 
the rescue of motor function by BDNF neural progenitors, while genetic mouse 
models showed fewer improvements. It is important to note that tumor formation 
was absent. The study also showed that adult neurogenesis was preserved in a 
BDNF-dependent manner. It was concluded that ESC-derived neural progenitors 
and BDNF are potential therapeutic strategies for HD to ameliorate neurodegenera-
tive symptoms [55, 56].
7. Conclusions
It is possible to conclude that BDNF is essential for the survival, phenotypic fea-
tures, and function of mature, fully developed neurons. In turn, changes in BDNF 
level or distribution seem to be important in the pathogenesis of neurodegenerative 
conditions in humans and especially in HD.
Preclinical studies over the past 20 years tested a possible neuroprotective role 
of BDNF in HD, which is a potent pro-survival and pro-differentiation factor for 
developing and adult neurons. Robust preclinical data in animals suggest that the 
neurotrophic action of BDNF alleviates both neuropathological and motor function 
deficits in the brain of patients with HD.
The intention of BDNF administration is suggested as a possible therapeutic 
strategy for patients with HD. However, clinical studies that used recombinant 
BDNF demonstrated a series of technical problems and the limited neuroprotective 

















Adenovirus — 48 4.73 ng 105 [53]
hBM-
MSC







Lentivirus — 24 10.9–18.1 ng 2 × 105 [54]
Table 3. 
BDNF secretion in BM-MSC transduced with BDNF.
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